In general, TNFAIP6, IFRD1, IFITM2, IFNGR1, and NFIL3 would be good markers for early diagnosis, since they are all present before the tumor formation in the model; however, IRF6 could be a good marker for tumor development in the patient, which could help to predict the response of the immune system in breast cancer patients. This evidence concerns the gene IFRD1 and breast carcinoma.